Zacks: Senesco Technologies Inc. (NYSE:ELOX) Receives Consensus Recommendation of “Buy” from Analysts

Senesco Technologies Inc. (NYSE:ELOX) has been given an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and three have assigned a strong buy rating to the company. Senesco Technologies’ rating score has declined by 7.1% from three months ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 12-month consensus target price of $13.75 for the company and are anticipating that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also given Senesco Technologies an industry rank of 92 out of 255 based on the ratings given to its competitors.

Shares of ELOX traded down $0.22 during trading hours on Tuesday, hitting $3.59. 116,900 shares of the stock were exchanged, compared to its average volume of 195,965. Senesco Technologies has a fifty-two week low of $2.87 and a fifty-two week high of $14.74. The business has a 50-day moving average of $4.69 and a 200-day moving average of $5.31.

About Senesco Technologies

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Story: S&P 500 Index

Get a free copy of the Zacks research report on Senesco Technologies (ELOX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Senesco Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies and related companies with's FREE daily email newsletter.